Ali Poyan Mehr, M.D. is the Founding President of the GlomCon Foundation, a nonprofit charitable 501(c)(3) organization providing medical education and enabling platforms for kidney disease research. He completed his medical degree at Charite Universitaets Medicine in Berlin, followed by postdoctoral research training at Yale University and nephrology and bioengineering at Harvard Medical School and Wyss Institute for Biomedical Engineering. Dr. Poyan Mehr was the inaugural Medical Director of Quality Improvement and Patient Safety in Nephrology at Beth Israel Deaconess Medical Center, where he led population health efforts for patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD). In this role, Dr. Poyan Mehr contributed to numerous innovative projects, such as developing the electronic KidneyTracker decision support system for CKD patients and receiving a Clinical Innovation Grant to help primary care physicians manage patients with chronic kidney disease. He received the Wyss Clinical Fellowship for his contributions to the biomedical engineering of microfluidics organs-on-chips development.

Dr. Poyan Mehr served as the Principal Investigator, Co-investigator, or scientific member on several Phase 1, Phase 2, and Phase 3 studies of new therapeutics for patients with kidney or cardiovascular disease, some published in the New England Journal of Medicine and Nature Medicine. 

Dr. Poyan Mehr is currently leading a Phase 2 randomized placebo-controlled trial funded by the National Heart, Lung, and Blood Institute in acute kidney injury in more than 300 patients.

He is the Director of the Regional Glomerular Disease Program at Kaiser Permanente Northern California and Kaiser Permanente’s Quality Lead for the National Kidney Care Services. 

His work has been recognized with multiple awards, including the Chief Academic Officer’s Pilot Grants Program and the ASN Carl W. Gottschalk Research Scholar Grant, and he has published in high-impact journals.